Oxycodone — Membership Pricing

Other medications in Pain & Inflammation

• Oxymorphone
• Pentazocine
• Piroxicam
• Sulindac
• Tapentadol
• Tizanidine
• Tramadol
• Tramadol-Acetaminophen

About Oxycodone

Oxycodone is a powerful opioid medication prescribed for moderate to severe pain. While highly effective, its cost can be a significant concern for many. TheDrugClub offers a valuable solution, providing members with access to discount pricing on prescriptions like oxycodone, helping you manage your health expenses more effectively.

Oxycodone is a potent opioid analgesic used to manage moderate to severe pain. It is commonly prescribed for acute pain following injuries or surgery, chronic pain conditions, and cancer-related pain when other treatments have proven insufficient. Due to its strength and potential for dependence, oxycodone is typically used for short periods or under strict

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Oxycodone is approved for (FDA label)

Oxycodone hydrochloride (HCl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including oxycodone HCl tablets for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.

Source: Read the full FDA label on DailyMed. Label effective date: July 23, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Oxycodone (FDA label)

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of oxycodone HCl, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of oxycodone HCl are essential [see Warnings and Precautions (5.2) ] . Accidental Ingestion Accidental ingestion of even one dose of oxycodone HCl, especially by children, can result in a fatal overdose of oxycodone [see Warnings and Precautions (5.2) ] . Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

Source: FDA prescribing information (DailyMed). Set ID: 6b6db42b-9821-4aa6-8566-297037d84079. SPL document ID: cf18b924-ef1c-4b84-9c6d-6977ee8b7407. Label effective date: July 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Oxycodone (FDA label)

Oxycodone HCl tablets, USP are available in following strength: Oxycodone HCl tablets USP, 5 mg are supplied as white, round, biconvex tablets debossed with “A” on the left and “04” on the right of the score on one side and plain on the other side. Oxycodone HCl tablets USP, 10 mg are supplied as pink, round, biconvex tablets debossed with “A” on the left and “48” on the right of the score on one side and plain on the other side. Oxycodone HCl tablets USP, 15 mg are supplied as green, round, biconvex tablets debossed with “A” on the left and “49” on the right of the score on one side and plain on the other side.

Source: FDA prescribing information (DailyMed). Set ID: 6b6db42b-9821-4aa6-8566-297037d84079. SPL document ID: cf18b924-ef1c-4b84-9c6d-6977ee8b7407. Label effective date: July 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Oxycodone (FDA label)

The following serious adverse reactions are described, or described in greater detail, in other sections: • Addiction, Abuse, and Misuse [see Warnings and Precautions (5.1) ] • Life-Threatening Respiratory Depression [see Warnings and Precautions (5.2) ] • Interactions with Benzodiazepines or Other CNS Depressants [see Warnings and Precautions (5.3) ] • Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions (5.4) ] • Opioid-Induced Hyperalgesia and Allodynia [see Warnings and Precautions (5.7) ] • Adrenal Insufficiency [see Warnings and Precautions (5.9) ] • Severe Hypotension [see Warnings and Precautions (5.10) ] • Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.12) ] • Seizures [see Warnings and Precautions (5.13) ] • Withdrawal [see Warnings and Precautions (5.14) ] Most common adverse reactions (≥3%) were nausea, constipation, vomiting, headache, pruritus, insomnia, dizziness, asthenia, and somnolence. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 6b6db42b-9821-4aa6-8566-297037d84079. SPL document ID: cf18b924-ef1c-4b84-9c6d-6977ee8b7407. Label effective date: July 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Oxycodone (FDA label)

Oxycodone HCl is contraindicated in patients with: • Significant respiratory depression [see Warnings and Precautions (5.2) ]. • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment or hypercarbia [see Warnings and Precautions (5.8) ]. • Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.12) ] . • Known hypersensitivity (e.g., anaphylaxis) to oxycodone [see Adverse Reactions (6.2) ] . • Significant respiratory depression. ( 4 ) • Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment. ( 4 ) • Known or suspected gastrointestinal obstruction, including paralytic ileus. ( 4 ) • Hypersensitivity to oxycodone. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 6b6db42b-9821-4aa6-8566-297037d84079. SPL document ID: cf18b924-ef1c-4b84-9c6d-6977ee8b7407. Label effective date: July 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Oxycodone (FDA label)

• Opioid-Induced Hyperalgesia and Allodynia: Opioid-Induced Hyperalgesia (OIH) occurs when opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. If OIH is suspected, carefully consider appropriately decreasing the dose of the current opioid analgesic, or opioid rotation. (5.7) • Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Regularly evaluate closely, particularly during initiation and titration. (5.8) • Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. (5.9) • Severe Hypotension: Regularly evaluate during dosage initiation and titration. Avoid use of oxycodone HCl in patients with circulatory shock. (5.10) • Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression.

Source: FDA prescribing information (DailyMed). Set ID: 6b6db42b-9821-4aa6-8566-297037d84079. SPL document ID: cf18b924-ef1c-4b84-9c6d-6977ee8b7407. Label effective date: July 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Oxycodone (FDA label)

Table 1 includes clinically significant drug interactions with oxycodone HCl. Table 1: Clinically Significant Drug Interactions with Oxycodone HCl Inhibitors of CYP3A4 and CYP2D6 Clinical Impact: The concomitant use of oxycodone HCl and CYP3A4 inhibitors can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of oxycodone HCl and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of oxycodone HCl is achieved [see Warnings and Precautions (5.3) ] . After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the oxycodone plasma concentration will decrease [see Clinical Pharmacology (12.3) ] , resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to oxycodone. Intervention: If concomitant use is necessary, consider dosage reduction of oxycodone HCl until stable drug effects are achieved.

Source: FDA prescribing information (DailyMed). Set ID: 6b6db42b-9821-4aa6-8566-297037d84079. SPL document ID: cf18b924-ef1c-4b84-9c6d-6977ee8b7407. Label effective date: July 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.